| |
The pattern of resistance mutants in a population of
heavily pretreated HIV infected patients
in a resource limited setting: Implications for salvage therapy.
P Patterson, A Krolewiecki, C Ochoa, et al
Abstract
|
| |
Drug class multi-resistance as main marker of disease progression and
poor survival after
genotype-guided antiretroviral salvage therapy
M Zaccarelli, V Tozzi, P Lorenzini,, et al
Abstract
|
| |
Ritonavir boosted double protease inhibitors in salvage therapy
M Shah, C Mihailidis, E Davies,, et al
Abstract
|
| |
The LOPSAQ salvage study: 48 week analysis of the full cohort treated
with lopinavir
(LPV/r) plus saquinavir (SQV) without any additional antiretroviral
(ART) therapy
S Staszewski, B Dauer, A Carlebach, et al
Abstract
|
| |
Two non-nucleosides association as part of salvage
therapy in highly pre-treated patients.
A Guelar, H Knobel, G Vallecillo,, et al
Abstract
|
| |
The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV)
and
saquinavir (SQV) in a ritonavir (RTV) boosted protease inhibitor therapy
regimen
NH von Hentig, A Mueller, A Haberl, et al
Abstract |
|
8th
Int Congress on Drug Therapy in HIV Infection
XII
International HIV Drug Workshop
HAART
Salvage Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
